Get started

TRTC

Watch List: Terra Tech Corp (USA: $TRTC) Looking Pretty💚💚💚Terra Tech Corp. cultivates, produces, and retails medical and adult use cannabis products. It offers cannabis-infused baked goods, chocolates, and candies; cannabis-infused topical products, such as lotions, massage oils and balms; clones of marijuana plants; flowers and concentrates; oils, waxes, hash, shatters, and clears under the IVXX brand name; and cartridges, vape pens, and wax products. The company also operates medical marijuana retail and adult use dispensaries under the Blüm brand in California and Nevada. Terra Tech Corp. was founded in 2010 and is headquartered in Irvine, California.
TLong
by Bullishcharts
2
Triple Bottom is In for Terra Tech - Standby for the AdvanceTriple bottom is in for Terra Tech on the day chart. Wait for the advance in the coming weeks. - Usually form over a 3 to 6 month period. CHECK. Dec 14 - Jun 19. - Prior Trend: With any reversal pattern, there should be an existing trend to reverse. In the case of the Triple Bottom Reversal, a clear downtrend should precede the formation. CHECK. Literally been in a downtrend since the beginning of time. - Three Lows: All three lows should be reasonably equal, well-spaced and mark significant turning points. The lows do not have to be exactly equal, but should be reasonably equivalent. CHECK. All three occurred in the .55 - .6 range. - Volume: As the Triple Bottom Reversal develops, overall volume levels usually decline. Volume sometimes increases near the lows. After the third low, an expansion of volume on the advance and at the resistance breakout greatly reinforces the soundness of the pattern. CHECK for decline in volume. Hope to see an expansion in volume over the coming weeks. - Resistance Break: As with many other reversal patterns, the Triple Bottom Reversal is not complete until a resistance breakout. The highest point of the formation, which would be the highest of the intermittent highs, marks resistance. Patience is a virtue...strong resistance at numerous levels above .8.
TLong
by danj371
Tetra Tech Corp. on 3rd falling wedge, await 7 life cat bouncewatching for entry, pulse, dead cat falling wedge for 3rd cycle (2014, 2016, 2018)...TBD About: Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production. The Herbs and Produce Products segment offers hydroponic herbs, produce, and floral products. The Cannabis Dispensary, Cultivation and Production segment operates medical marijuana retail and adult use dispensaries under the name Blum, which provides a selection of medical and adult use cannabis products, such as flowers, concentrates, and edibles; and produces and sells a line of medical and adult use cannabis flowers, as well as a line of medical and adult use cannabis-extracted products comprising concentrates, cartridges, vape pens, and wax products in California and Nevada. Terra Tech Corp. was founded in 2010 and is headquartered in Irvine, California. $122M Cap, down 52% YTD, $38.5M rev. 7-1YOY, rev gr. 38%, 127K shares bought by insiders last 2 yr. (strong), Inst. MF hold 0%, while wealth manag. <1%, so mostly private investors, so high upside if legallized, earnings range -0.30 (3/8) to 0 (1/8), so still not profitable pop needed (11/7/18 next announcement). 8.7.18 was -0.17. The rapidly rising demand for Cannabidiol (CBD) and Hemp based products is showing no signs of slowing down as expectations to push both markets into new territories with exploding sales value in the next coming years. The global industrial hemp market size is expected to reach USD $10.6 billion by 2025, according to a new report by Grand View Research, Inc. and the market is anticipated to expand at a CAGR of 14.0%. The North American CBD market is primed for expansive growth across its three primary sectors, hemp-derived CBD, marijuana-derived CBD and pharmaceutical CBD. With recent developments and advancements in the hemp industry, farmers across the country are turning their attention to commercialization looking for the road to profitability. Increasing R&D activities to develop perfect agronomy and new genetics of crops to obtain high yield and improved product quality are expected to have a positive impact on CBD - Hemp production. Active Companies from around the market with current developments this week include: Marijuana Company of America (MCOA), Inc., GrowLife (PHOT), Inc. MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF), Kush Bottles, Inc.(KSHB), Terra Tech Corp (TRTC)
TLong
by Pokethebear
$EHVVF Continues to Move in Anticipation of Canadian MJ+ Updates"We have executed and expanded the commitments we have made to our mental health (Multi Health Systems) and therapeutic partners (MedReleaf TSX: LEAF), entered new partnerships to expand our market verticals to include the pharmaceutical industry (Aequus TSX-V: AQS). Meanwhile, we have been preparing for our next set of trials of our new video games for assessment & remediation of ADD/ADHD developed in collaboration with The Hospital for Sick Children in Toronto." "Pharmaceutical Trials In July 2017, we signed a Letter of Intent with Aequus Pharmaceuticals for Ehave solutions to be used for the assessment, diagnostic, therapeutic and outcome management for use in informal and formal clinical trials. The intent is for the Ehave Platform and patient reported outcomes application to be used by clinicians and patients of Aequus trials, with content to be customized based on the specific needs of the trial protocols for both traditional and Cannabis CBD-based treatments. This is a significant milestone for Ehave – opening up a new market vertical to demonstrate the value of the Ehave informatics platform in clinical trails. We believe that we can bring the cost of trials down substantially and be the first Digital CRO in the market." "We have a management team that has built, grown and operated high value organizations before, including my experience in building a $10M cancer informatics solution for Princess Margaret Cancer Center, being an executive at Mount Sinai Hospital in Toronto that had a $330M operating budget, the $40M exit of Casero to Radial Point where I was a founding employee, and being an early employee of Solect Technology Group which sold to Amdocs for $1.2B. In addition, we have a world class Board of Directors with health technology, pharmaceutical and insurance expertise." 13g Filed A/H's Nov, 9th 2017 Name of Person Filing EISENBERG FAMILY FOUNDATION, INC. Income of over $100 Million. www.taxexemptworld.com ih.advfn.com
OTC:EHVVFLong
by StockGuild
$OWCP Bullish Pennant Formation with Upcoming MJ Catalysts News ANNUAL REPORT CLARIFICATION FOR SHAREHOLDERS: 1) Page 5: Don't get confused by the OWCP already done Psoriasis study (where efficacy results are imminent) and next deeper and extended studies planned from April: "On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Company determined to extend the size and scope of the Study for the purpose, among other things, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study during the 2 nd or 3 rd quarters of 2017." The study already done is confirmed in page 36: "We have been conducting a study on the efficacy of the cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 " While the extended study to start in April 2017 according to previous 8K is the safety phase and identification of biological markers useful to identify potential other application of the cream (Skin Cancer imo): "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments" 2) Page 5-6: Multiple Myeloma Amazing News for Shareholders is here: "Dr. Leiba led our in vitro studies on the effect of a formulation comprised of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cells studied outside their normal biological context. The results indicated a 100% mortality rate of myeloma cells in 80% of the cultured cells within a 24 to 48-hour period, and highlight the potential abilities of cannabis oil extract to fight multiple myeloma cancer cells. We believe that the results of this study indicate a potential to develop a more effective treatment for multiple myeloma than standard therapies." "Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and received its approval to commence a clinical study" "Intend to commence a clinical study in the third quarter of 2017" 3) Notes on competition page 7: For Psoriasis they aim to attack Big Pharma market and they are well aware of current products and thier limitation: "The current common treatments for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A (by Novartis), methotrexate or MTX and biological drugs such as Enbrel (by Amgen), Amevive (by Biogen but whose patent expired in 2013) and Ustakinumabn (by Janssen Immunology)." This is excelent Marketing strategic approach; 4) Page 8: Provisional Patents are listed in report, can be downloaded through reference number and are real! They are extremely well written in a professional way and full of interesting claims: when needed (close to deadline) they will pay the service fees and transform them in Official US Permanent Patent; Why to do it before if the provisional is free of charge? Smart approach; 5) Page 12: CERTIFICATION and FDA approval all diligently work has been done according to standard: " Israel’s Ministry of Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members of Israel’s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate, teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States
OTC:OWCPLong
by StockGuild
The entire sector has fallenThe entire Cannabis OTC sector seems to be in absolute peril the last few days. I know many are cutting their losses and getting out, so forgive me for being a bit of a bag holder now and and buckling in for the storm. I do not know how much further down this will go, nobody does. I've lost about $800 or so since opening today on this stock, but I'm still going to gamble here and hold this through Jan/Feb and reevaluate then. I don't know why we're dumping across the sector this week, other than people bought the hype and sold the news. Looking at MJNA's lifetime chart, some of the historic runups in price came Jan/Feb so I'm optimistic for the future of Cannabis as an investment. I don't think 2 days of straight dumps after legalization in some major states is representative of the sector as a whole long term. Lets see. If you're holding with me, buckle up!
OTC:MJNALong
by Cryptocol
2